Risk of adverse events among older adults following co-prescription of clarithromycin and statins notmetabolized by cytochrome P450 3A4.
Among older adults taking a statin not metabolized by CYP3A4 (rosuvastatin/pravastatin/fluvastatin), co-prescription of clarithromycin versus azithromycin was associated with a modest but statistically significant increase in the 30-day absolute risk of adverse outcomes, including AKI and admission with hyperkalemia.
:
Treatment of Kidney Transplant Recipients With ACEi/ARB and Risk of Respiratory Tract Cancer: A Collaborative Transplant Study Report
Novartis announces termination of ALTITUDE study
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Acute Kidney Injury Internal Medicine for Nephrologists Source Type: research
More News: Azithromycin | Biaxin | Cancer | Cancer & Oncology | Cholesterol | Clarithromycin | Crestor | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fluvastatin | Internal Medicine | Kidney Transplant | Kidney Transplantation | Pravastatin | Respiratory Medicine | Rosuvastatin | Statin Therapy | Statistics | Study | Transplant Surgery | Transplants | Urology & Nephrology | Zithromax